We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the diagnostic efficacy of noninvasive diagnosis in patients with chronic viral hepatitis B complicated with nonalcoholic fatty liver disease and significant liver fibrosis.
- Authors
DOU Jing; Abulimiti, LITIFU; WANG Xiao-zhong
- Abstract
Objective: To evaluate the diagnostic efficacy of chronic viral hepatitis B (CHB) with significant liver fibrosis (S2) in patients with nonalcoholic fatty liver disease (NAFLD) by using noninvasive diagnosis and their combined models, and to explore their clinical features. Methods: A total of 104 inpatients with CHB diagnosed and complicated with NAFLD (hepatic steatosis suggested by liver biopsy) were retrospectively collected from January 2018 to January 2023 in the Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University. Liver biopsy was performed in all patients. General data, laboratory test results, liver hardness (LSM), FIB-4, APRI, GGT/PLT, AST/PLT and other results of patients were collected and grouped according to different fibrosis stages (S) to explore the clinical and pathological characteristics of patients with <S2 and S2 stages. Receiver operating characteristic curve was used to evaluate the diagnostic value of LSM, FIB-4, APRI, GGT/PLT, AST/PLT and their combined models in patients with significant liver fibrosis in CHB patients with NAFLD.Results: Among the 104 patients, there were 55 patients had S1 fibrosis, 32 patients had S2 fibrosis, 11 patients had S3 fibrosis and 6 patients had S4 fibrosis. Patients had <S2 fibrosis, ALT 33.75±17.15 U/L, AST 24.00(19.77,29.00) U/L, inflammation above G2 stage accounted for 92.72%, GGT/PLT 0.07(0.10,0.15), AST/PLT 0.09(0.10,0.15), LSM 8.70(6.80,10.10) kPa, FIB-4 1.07±0.51, APRI 0.26(0.22,0.28). In patients S2 fibrosis, ALT 42.14±21.39 U/L, AST 29.04(24.00,40.32) U/L, inflammation above G2 stage accounted for 97.95%, GGT/PLT 0.15(0.10,0.28), AST/PLT 0.14(0.10,0.26), GGT/PLT 0.15(0.10,0.28), AST/PLT 0.14(0.10,0.26). LSM 11.80(8.50,16.65) kPa, FIB-4 1.39±0.72, APRI 0.35(0.26,0.66), the difference between the two groups was statistically significant (P<0.05). The area under the receiver operator characteristic curves of the subjects of LSM, FIB-4, APRI, GGT/PLT and AST/PLT were 0.716, 0.623, 0.669, 0.644 and 0.669 (P<0.05), respectively. In the combined model, the area under the receiver operator characteristic curves of LSM combined with FIB-4, LSM combined with APRI, LSM combined with GGT/PLT and LSM combined with AST/PLT were 0.712, 0.719, 0.715 and 0.719, respectively (P<0.05). Conclusion: Although the currently commonly used Noninvasive diagnosis of liver fibrosis has certain diagnostic efficacy for significant liver fibrosis in CHB complicated with NAFLD, it cannot replace liver biopsy. Noninvasive Diagnosis can be used as an auxiliary method for regular clinical evaluation of liver biopsy.
- Subjects
FATTY liver; HEPATIC fibrosis; NON-alcoholic fatty liver disease; CHRONIC hepatitis B; NONINVASIVE diagnostic tests; RECEIVER operating characteristic curves
- Publication
Journal of Hainan Medical University, 2023, Vol 29, Issue 20, p19
- ISSN
1007-1237
- Publication type
Article